Suspected cardiac amyloidosis: Endomyocardial biopsy remains the diagnostic gold-standard [2]

American Journal of Hematology

Volumn 82, Issue 4, 2007, Pages 328-

  Kristen, Arnt V ^a   Dengler, Thomas J ^a   Katus, Hugo A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOIDOSIS; CLINICAL ARTICLE; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; HYPERTENSION; LETTER; PERICARDIAL EFFUSION; PRIORITY JOURNAL;

AMYLOIDOSIS; BIOPSY; CARDIOMYOPATHIES; HUMANS; HYPERTROPHY; MYOCARDIUM; SENSITIVITY AND SPECIFICITY;

EID: 34147098487     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20745     Document Type: Letter

References (5)

1. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on amyloid and amyloidosis. Am J Hematol 2005;79:319-328.
2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
3. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-2060.
4. Perz JB, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: A single centre prospective phase II study. Br J Haematol 2004;127:543-551.
5. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential cardiac and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2005;107:1227-1229.